Clinical Trial Update: Clinical Study of XNW5004 Tablets in the Treatment of Relapsed and Refractory Follicular Lymphoma [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial of XNW5004 Tablets for relapsed and refractory follicular lymphoma is currently recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Follicular Lymphoma

Drugs mentioned

• XNW5004 Tablets

Snippet

Sponsor: Evopoint Biosciences Inc. | Conditions: Follicular Lymphoma, Grade 1, Follicular Lymphoma, Grade 2 | Phase 2 | Status: RECRUITING